Business Context and Reporting Period
This Form 6-K filing by Compugen Ltd., an Israeli biotechnology company, was submitted on August 20, 2008. The filing incorporates a press release and serves as a proxy statement for the Annual General Meeting of Shareholders scheduled for September 24, 2008. The document details corporate governance matters, including the election of directors, executive compensation adjustments, and the appointment of independent auditors.
Key Financial Metrics
The filing text does not provide specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity for the reporting period. The document focuses exclusively on corporate actions and shareholder meeting logistics.
- Outstanding Shares: 28,482,440 ordinary shares as of August 15, 2008.
- Shareholders of Record: 88 total holders, with 57 registered in the United States holding approximately 89% of outstanding shares.
Material Changes and Corporate Actions
The filing outlines three primary proposals for shareholder approval:
- Election of Directors: Re-election of Prof. Ruth Arnon, Mr. Martin Gerstel (Chairman), and Mr. Alex Kotzer (CEO) to the Board of Directors.
- Executive Compensation: Approval of a bonus package for CEO Alex Kotzer consisting of 15,000 ordinary shares and a cash bonus grossed up for taxes. Additionally, approval of 150,000 stock options exercisable at the last closing price on NASDAQ on the meeting date, vesting monthly over four years. The proposal also includes an amendment to Mr. Kotzer's employment agreement to broaden severance provisions to include resignation or termination after December 31, 2008, or following a strategic transaction.
- Auditor Appointment: Appointment of Kost, Forer, Gabbay & Kasierer (a member of Ernst & Young Global) as the independent auditors for the fiscal year ending December 31, 2008.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, forward-looking statements regarding business outlook, or a discussion of specific financial risks or contingencies. The document notes that the Board of Directors recommends shareholders vote "FOR" all three proposals. It also states that if a quorum is not present at the scheduled meeting time, the meeting will be adjourned to October 1, 2008.
Important Facts for Investor Verification
- Verify the impact of the proposed 150,000 stock options and 15,000 bonus shares on existing shareholder dilution.
- Review the specific terms of the amended severance provision for the CEO, particularly the inclusion of resignation scenarios post-December 31, 2008.
- Confirm the voting record date of August 15, 2008, to determine eligibility for the September 24, 2008 meeting.
- Check the company's Annual Report on Form 20-F for the actual financial performance data not included in this proxy statement.